Kelly Dooley, MD

Role: 
Faculty
Associate Professor of Medicine, Pharmacology, and Molecular Sciences

Dr. Dooley is an Associate Professor of Medicine, Pharmacology, and Molecular Sciences at Johns Hopkins University School of Medicine, with appointments in the Divisions of Clinical Pharmacology and Infectious Diseases. She is also a faculty member at the Center for Clinical Global Health Education.

Dr. Dooley has an HIV outpatient practice and attends on the inpatient HIV service. Her research focuses on tuberculosis therapeutics with an emphasis on Phase I or II clinical trials of new or existing TB drugs and treatment of HIV/TB co-infection. She is Principal Investigator or Protocol Chair for several clinical trials involving TB drugs for drug-sensitive TB or drug-resistant TB and involved in the scientific committees of the Tuberculosis Trials Consortium, AIDS Clinical Trials Group, and IMPAACT networks. She has a special interest in optimizing TB drugs for special populations, including children and pregnant women.>

Dr. Dooley received her MD from Duke University, and completed residency training in internal medicine and an infectious diseases fellowship at Johns Hopkins School of Medicine. She is board certified in internal medicine and infectious diseases.

The global neurological burden of tuberculosis

Post Date: 
2018-05-18
Publication: 
Seminars in Neurology
Central nervous system (CNS) involvement of tuberculosis (TB) is the most severe manifestation of TB and accounts for approximately 5 to 10% of all extrapulmonary TB (EPTB) cases and approximately 1% of all TB cases. TB meningitis (TBM) is the most common form of CNS TB, though other forms...

Suboptimal antituberculosis drug concentrations and outcomes in small and HIV‐coinfected children in India: Recommendations for dose modifications

Post Date: 
2017-12-16
   |   
Countries: 
Publication: 
Clinical Pharmacology and Therapeutics
This work aimed to evaluate the once-daily antituberculosis treatment as recommended by the new Indian pediatric guidelines. Isoniazid, rifampin, and pyrazinamide concentration-time profiles and treatment outcome were obtained from 161 Indian children with drug-sensitive tuberculosis...

Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis

Post Date: 
2017-12-07
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
PLOS One
PLOS One: Mave and colleagues compared TB drug exposure in plasma and hair samples among a small cohort of children.

Suboptimal anti-tuberculosis drug concentrations and outcomes in small and HIV coinfected children in India: recommendations for dose modifications

Post Date: 
2017-12-01
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Clinical Pharmacology and Therapeutics
This work aimed to evaluate the once-daily anti-tuberculosis treatment as recommended by the new Indian pediatric guidelines. Isoniazid, rifampin and pyrazinamide concentration-time profiles and treatment outcome were obtained from 161 Indian children with drug-sensitive tuberculosis...

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

Post Date: 
2017-03-24
Publication: 
The Lancet Respiratory Medicine
Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia. Although tuberculosis control has been effective in some regions of the world, these gains are threatened by the increasing...

Tuberculosis associated with HIV infection

Post Date: 
2017-01-15
Publication: 
Microbiology Spectrum
Abstract Tuberculosis (TB) has recently surpassed HIV as the primary infectious disease killer worldwide, but the two diseases continue to display lethal synergy. The burden of TB is disproportionately borne by people living with HIV, particularly where HIV and poverty...

Bedaquiline

Post Date: 
2017-01-01
Publication: 
Kucers’ the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, and Antiviral Drugs, 7th Edition
Section II, Antibiotics: Part 12 Anti-tuberculosis drugs.

Isoniazid hair concentrations in children with tuberculosis: a proof of concept study

Post Date: 
2016-06-01
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
International Journal of Tuberculosis and Lung Disease
Assessing treatment adherence and quantifying exposure to anti-tuberculosis drugs among children is challenging. We undertook a 'proof of concept' study to assess the drug concentrations of isoniazid (INH) in hair as a therapeutic drug monitoring tool. Children aged <12 years initiated on...

Toward earlier inclusion of pregnant and postpartum women in TB drug trials: consensus statements from an International Expert Panel

Post Date: 
2016-01-04
Publication: 
Clinical Infectious Diseases
Tuberculosis is a major cause of morbidity and mortality in women of childbearing age (15–44 years). Despite increased tuberculosis risk during pregnancy, optimal clinical treatment remains unclear: safety, tolerability, and pharmacokinetic data for many tuberculosis drugs are lacking, and...

Pediatric tuberculous meningitis: model-based approach to determining optimal doses of anti-tuberculosis drugs for children

Post Date: 
2015-10-22
   |      |   
Clinical Sites: 
Publication: 
Clinical Pharmacology and Therapeutics
Pediatric tuberculous meningitis (TBM) is a highly morbid, often fatal disease. Standard treatment includes isoniazid, rifampin, pyrazinamide, and ethambutol. Current rifampin dosing achieves low cerebrospinal fluid (CSF) concentrations, and CSF penetration of ethambutol is poor. In adult...

Safety, tolerability, and pharmacokinetic interactions between single-dose TMC207 and steady-state efavirenz in healthy volunteers: AIDS Clinical Trials Group (ACTG) Study.

Post Date: 
2012-04-15
   |   
Countries: 
Publication: 
Journal of Acquired Immune Deficiency Syndromes
Background: Drug-drug interactions complicate management of coinfection with HIV-1 and Mycobacterium tuberculosis. Bedaquiline (formerly TMC207), an investigational agent for the treatment of tuberculosis, is metabolized by cytochrome P450 (CYP) 3A which may be induced by the antiretroviral...

Pages